Hutchmed announces approval of NDA for Orpathys, Tagrisso combination in China

Hutchmed (HCM) announced that the new drug application for the combination of Orpathys and Tagrisso has been granted approval by the China National Medical Products Administration for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor mutation-positive non-squamous non-small cell lung cancer with MET amplification after disease progression on EGFR tyrosine kinase inhibitor therapy. This approval also triggers a $11M milestone payment from AstraZeneca (AZN), which markets both Orpathys and Tagrisso in China.